Senator moves to ban drug sold as bath salts

NEW YORK Mon Jan 31, 2011 11:45am EST

Related Topics

NEW YORK (Reuters) - Two drugs that produce a "meth-like" high and are being sold under the guise of "bath salts" would be banned as federally controlled substances under a bill unveiled by U.S. Senator Charles Schumer of New York.

"These so-called bath salts contain ingredients that are nothing more than legally sanctioned narcotics, and they are being sold cheaply to all comers, with no questions asked, at store counters around the country," said Schumer, a Democrat.

Schumer said he will introduce a bill to outlaw the two synthetic drugs -- mephedrone and methylenedioxypyrovalerone, or MDPV. The drugs come in powder and tablet form and are ingested by snorting, injection, smoking and, less often, by use of an atomizer.

Users experience an intense high, euphoria, extreme energy, hallucinations, insomnia and are easily provoked to anger, according to the Drug Enforcement Administration, which is currently investigating the drugs.

They have emerged as legal alternatives to cocaine and methamphetamines, and one or both have already been banned in the European Union, Australia, Canada, and Israel. In the United States, Florida, Louisiana and North Dakota have all recently banned the substances.

"The longer we wait to ban the substance, the greater risk we put our kids in," Schumer said.

Media reports over the last year describe the drugs as becoming increasingly popular, particularly among young people attending nightclubs, although the actual number of individuals using the drugs is unknown.

"These products are readily available at convenience stores, discount tobacco outlets, gas stations, pawnshops, tattoo parlors, truck stops and other locations," said an alert issued by the DEA.

"Prices range from $25 to $50 per 50-milligram packet," the DEA alert said.

The European Union banned mephedrone in December, saying the drug was directly linked to the deaths of two people, and may have been tied to 37 other cases of death.

The European Union's report said there was limited scientific evidence on the effects of the drug -- believed to be mostly manufactured in Asia before being packaged in the West -- but that there was sufficient evidence of its health risks to support a ban.

Schumer has also asked the health commissioner of New York State, Nirav Shah, to ban the two substances.

(Reporting by Jonathan Allen; Editing by Barbara Goldberg and Jerry Norton)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (10)
MBrewer wrote:
Makes me wonder when I hear phrases like, ” …the greater risk we put our kids in,” from the same government that allows GMO foods to be eaten by children, or anyone for that matter.

Jan 31, 2011 1:14pm EST  --  Report as abuse
WRL wrote:
It’s interesting how this article covers the cost, use, and high-inducing effects of these drugs but doesn’t give nearly as much attention to the negative consequences. An oblique reference to a few deaths with no real details is all that is offered.

Jan 31, 2011 1:21pm EST  --  Report as abuse
r-turo wrote:
To WRL:

When I was in my teens growing up in Southeast Iowa the D.A.R.E. program had a vehicle trailer they pulled around to different locations to heighten awareness of the Public to be on the lookout for Meth production in the neighborhoods. Looking back, I can’t help but see how the contents of the trailer only helped people know what to do and what they might need to make Meth. Within the next few months and over the course of the next Decade Meth production increased dramatically in the Mid-West.

Jan 31, 2011 3:16pm EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.